Biden’s HHS Bids Farewell With List Of 15 Drugs, Including GLP-1s, For Next Negotiations

By Gabrielle Wanneh, Donna Haseley / January 17, 2025 at 8:40 AM

The Biden administration on Friday (Jan. 17) announced the 15 drugs -- which include GLP-1 diabetes drugs, cancer and asthma treatments -- it has selected for the next round of Medicare price negotiation, unveiling the list before the Feb. 1 deadline in an apparent attempt to shape the next round of price talks before the Trump administration takes over Monday (Jan. 20).

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.

FEATURES

NEWSLETTERS

ABOUT US

Inside Health Policy is a subscription-fee-based daily digital news service from Inside Washington Publishers.

SITE LICENSES

Economical site license packages are available to fit any size organization, from a few people at one location to company-wide access. For more information on how you can get greater access to Inside Health Policy for your office, contact Online Customer Service at 703-416-8505 or healthpolicy@iwpnews.com.

STAY CONNECTED

Biden’s HHS Bids Farewell With List Of 15 Drugs, Including GLP-1s, For Next Negotiations

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.